Scribd
Upload
101 views1 page

Lurasidone

This study compared the efficacy and safety of lurasidone and risperidone for treating schizophrenia. Fifty patients were randomly assigned to receive either lurasidone titrated up to 80mg/day or risperidone titrated up to 6mg/day for 6 weeks. Both drugs significantly improved symptoms as measured by the PANSS scale, though there was no significant difference between the drugs. Weight gain occurred in both groups. Risperidone caused greater metabolic side effects like increased cholesterol and triglycerides. Lurasidone and risperidone 6mg doses were found to be equally effective and safe options for treating schizophrenia.

Uploaded by

Raju Teach Kaps
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
101 views1 page

Lurasidone

This study compared the efficacy and safety of lurasidone and risperidone for treating schizophrenia. Fifty patients were randomly assigned to receive either lurasidone titrated up to 80mg/day or risperidone titrated up to 6mg/day for 6 weeks. Both drugs significantly improved symptoms as measured by the PANSS scale, though there was no significant difference between the drugs. Weight gain occurred in both groups. Risperidone caused greater metabolic side effects like increased cholesterol and triglycerides. Lurasidone and risperidone 6mg doses were found to be equally effective and safe options for treating schizophrenia.

Uploaded by

Raju Teach Kaps
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

A RANDOMIZED, PROSPECTIVE COMPARATIVE STUDY TO EVALUATE

THE EFFICACY AND SAFETY OF LURASIDONE AND RISPERIDONE IN

TREATMENT OF SCHIZOPHRENIA

Background: Schizophrenia is a most disabling psychiatric disorder with prevalence


of around 1% in general population. Atypical antipsychotics are the cornerstone
treatment option which are equal in efficacy and different in adverse effect profile.
This study was designed to evaluate the efficacy and safety of lurasidone and
risperidone in schizophrenia patients.

Method: A total of 50 schizophrenia patients were randomly assigned to two


groups.25 patients received lurasidone starting dose of 40mg /day titrated up to
80mg/day and 25 patients received risperidone starting dose of 4mg/day titrated up to
6mg/day for 6 weeks.Efficacy was evaluated using relevant statistical analysis by
comparing the change from baseline to week 4 and 6 in Positive and Negative
Syndrome Scale (PANSS) and in adverse effects profile.

Results: Treatment with both lurasidone and risperidone was associated with
significantly greater improvement at week 4 and 6 on PANSS total score, PANSS
positive and negative subscale scores. But the difference between both groups in all
scores were statistically insignificant. The increase in weight gain and BMI from
baseline to 6 weeks was significant in both groups. There was statistically significant
increase in total cholesterol, triglyceridesand significant decrease in HDL level only in
risperidone group. Weight gain and tremor were the most frequent adverse drug
reactions in both groups. The incidence of extrapyramidal side effects was higher in
risperidone group.

Conclusion: Lurasidone 80 mg and risperidone 6mg doses administered once-daily,


were safe and equally efficacious for patients with schizophrenia.

Key words: Schizophrenia, Lurasidone, Risperidone, PANSS

You might also like